cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pharvaris Nv
3 own
6 watching
Current Price
$9.46
$0.04
(0.42%)
logo-phvs
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
319.63M
52-Week High
52-Week High
27.5
52-Week Low
52-Week Low
1.77
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization319.63M
icon52-Week High27.5
icon52-Week Low1.77
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Pharvaris Nv do?
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More
News & Events about Pharvaris Nv.
Ticker Report
11days ago
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have been given an average recommendation of Moderate Buy by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued...
PR Newswire
1month ago
Thinking about buying stock in Neurobo Pharmaceuticals, Palantir Technologies, Pharvaris NV, Li Auto, or IQIYI? Thinking about buying stock in Neurobo Pharmaceuticals, Palantir Technologies, Pharvaris NV, Li Auto, or IQIYI? PR Newswire NEW YORK, Dec. 9, 2022 NEW YORK, Dec. 9, 2022 /PRNewswire...
Benzinga
1month ago
read more...
Globe Newswire
2 months ago
ZUG, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced it will be presenting two in-person ePoster Meet the Author ...
Zolmax
2 months ago
Pharvaris (NASDAQ:PHVS Get Rating) has received an average recommendation of Hold from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a ...
Frequently Asked Questions
Frequently Asked Questions
What is Pharvaris Nv share price today?
plus_minus_icon
Can Indians buy Pharvaris Nv shares?
plus_minus_icon
How can I buy Pharvaris Nv shares from India?
plus_minus_icon
Can Fractional shares of Pharvaris Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Pharvaris Nv stocks?
plus_minus_icon
What is today’s traded volume of Pharvaris Nv?
plus_minus_icon
What is today’s market capitalisation of Pharvaris Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Pharvaris Nv?
plus_minus_icon
What percentage is Pharvaris Nv down from its 52-Week High?
plus_minus_icon
What percentage is Pharvaris Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$9.46
$0.04
(0.42%)
logo-phvs
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00